Is Bliss GVS Pharma overvalued or undervalued?

Jun 30 2025 08:01 AM IST
share
Share Via
As of June 27, 2025, Bliss GVS Pharma's valuation has shifted from attractive to fair, with a PE ratio of 19.63, an EV to EBITDA of 12.07, and a ROE of 8.03%, indicating moderate valuation compared to peers like Sun Pharma and Dr. Reddy's Labs, while its stock has significantly outperformed the Sensex over the past year.
As of 27 June 2025, the valuation grade for Bliss GVS Pharma has moved from attractive to fair, indicating a shift in perception regarding its market value. The company is currently fairly valued based on its financial ratios, which include a PE ratio of 19.63, an EV to EBITDA of 12.07, and a ROE of 8.03%.

In comparison to its peers, Bliss GVS Pharma's valuation appears moderate; for instance, Sun Pharma has a significantly higher PE ratio of 35.42, while Dr. Reddy's Labs, another attractive peer, has a PE of 19.23. The company’s recent stock performance has outpaced the Sensex over the past year, returning 54.05% compared to the Sensex's 6.08%, which may suggest positive market sentiment despite the current valuation grade.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read